Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

27.28 +0.32 (+1.19%)
Official Closing Price Updated: 7:00 PM EDT, Mar 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
News headline image
NVO Stock Is Rising Pre-Market – What Is The Wegovy News Driving Novo Nordisk Shares? ↗
The United Kingdom’s Medicines and Healthcare products Regulatory Agency on Friday announced that it had approved a maximum dose of up to 7.2 milligrams a week for Novo’s Wegovy earlier this month. 
Via Stocktwits
News headline image
3 Cash-Producing Stocks with Questionable Fundamentals
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
1 Healthcare Stock Worth Your Attention and 2 We Avoid
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have... 
Via StockStory
Topics Stocks
News headline image
1 Profitable Stock with Solid Fundamentals and 2 We Brush Off
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
Topics Bankruptcy
Most active S&P500 stocks in Tuesday's session ↗
Via Chartmill
News headline image
"Animal Spirits" Return: Morgan Stanley Signals M&A Renaissance as Healthcare and Industrials Lead Shifting Landscape
As 2026 begins, the global mergers and acquisitions (M&A) market is witnessing a profound "renaissance," driven by a confluence of stabilizing interest rates, record levels of corporate cash, and a... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
These S&P500 stocks are the most active in today's session ↗
Via Chartmill
News headline image
The Execution Engine: How Merck is Dominating the 2026 Pharma Landscape
As of January 15, 2026, Merck & Co. (NYSE: MRK) has emerged as the standout performer in the pharmaceutical sector, defying the gravity of looming patent expirations with a series of strategic... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Healthcare Titan Ascendant: Johnson & Johnson Hits All-Time Highs as It Navigates a New Political and Clinical Era
As of January 15, 2026, Johnson & Johnson (NYSE: JNJ) has emerged as the undisputed pacesetter of the healthcare sector, with its stock price surging to an all-time high of $218.53. This milestone... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Earnings
News headline image
3 Volatile Stocks We Keep Off Our Radar
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared. 
Via StockStory
Curious about the most active S&P500 stocks in today's session? ↗
Via Chartmill
News headline image
The Great Tariff-Inflation Tug-of-War: Why the Fed’s 2% Target Remains Elusive in 2026
As the United States enters the first quarter of 2026, the global economy is grappling with a radical shift in trade dynamics that has upended decades of globalization. The aggressive... 
Via MarketMinute
Topics Economy Supply Chain World Trade
News headline image
Viatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation
Date: January 14, 2026 Viatris Inc. (NASDAQ: VTRS) stands at a critical crossroads in early 2026. After years of functioning as a complex, debt-laden conglomerate formed from the massive merger of... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot
Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period... 
Via Finterra
Topics Initial Public Offering Intellectual Property
News headline image
Is It Time to Dump Your Shares of Eli Lilly? ↗
What happens with Eli Lilly's GLP-1 shot now that Novo Nordisk has come out with a GLP-1 pill? 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Great Recalibration: Why 2026 Could Be Healthcare’s Year to Rebound
For the past two years, the U.S. healthcare sector has been the forgotten stepchild of the equity markets. As the S&P 500 (SPX) surged on the back of an artificial intelligence gold rush and a... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance
Date: January 13, 2026 Introduction Amgen Inc. (NASDAQ: AMGN) finds itself at a historic crossroads. Long regarded as the "blue-chip" anchor of the biotechnology sector, the Thousand Oaks-based giant... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
The Evolution of a Giant: A Deep Dive into the ‘New’ Johnson & Johnson (JNJ) in 2026
As of January 13, 2026, Johnson & Johnson (NYSE: JNJ) stands at a pivotal juncture in its nearly 140-year history. Once a sprawling conglomerate synonymous with baby shampoo and Band-Aids, the "New... 
Via PredictStreet
Topics Artificial Intelligence Bankruptcy Economy
News headline image
3 Value Stocks That Fall Short
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
News headline image
Why Tempus AI Stock Rose Today ↗
The data provider's artificial intelligence-driven solutions are accelerating drug discovery. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape
As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the... 
Via MarketMinute
Topics Economy Intellectual Property World Trade
News headline image
Pfizer CEO Eyes Big Push Towards Obesity Drug Development In 2026 After $10B Metsera Acquisition ↗
Pfizer’s CEO Albert Bourla is looking to initiate about 10 late-stage trials of the company’s new obesity drugs. 
Via Stocktwits
Stay informed about the most active stocks in the S&P500 index on Monday's session. ↗
Via Chartmill
News headline image
Pfizer Cancer Combo Drug Shows Strong Tumor Shrinkage in Colorectal Cancer Trial ↗
Pfizer shared new trial data showing its cancer drug combo helped shrink tumors more often than standard treatment in advanced colorectal cancer patients at a major oncology meeting. 
Via Benzinga
News headline image
This ETF Is Proof That the Healthcare Rebound Is Real ↗
Via MarketBeat
Topics ETFs
News headline image
This Healthcare Stock Could Be One of the Best Companies to Own in 2026 ↗
It has strong momentum thanks to its current portfolio and several catalysts on the horizon. 
Via The Motley Fool
News headline image
Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer
From Pfizer Inc.
Via Business Wire
News headline image
Unusual Options Activity in Pfizer: 2 Strategies Traders Are Jumping On
There were 1,399 unusually active options in Thursday’s trading. Pfizer’s March 20 $29 put had the highest Vol/OI ratio at 210.16. In the money by 12.8%, it sets up for a couple of different trading... 
Via Barchart.com
News headline image
Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge
Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by... 
Via MarketMinute
News headline image
The Great Pricing Pivot: Novo Nordisk Launches Wegovy Pill in Bid to Reclaim US Market Dominance
As the first full week of 2026 unfolds, the pharmaceutical landscape is witnessing a seismic shift led by the Danish healthcare giant Novo Nordisk (NYSE: NVO). On January 5, 2026, the company... 
Via MarketMinute
Topics Economy
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.